Description: Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company primarily develops Felix, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid oxidative stress assay; and AI-Port. In addition, the company offers ambient temperature storage product for human sperm. Memphasys Limited was incorporated in 2006 and is based in Homebush, Australia.
Home Page: www.memphasys.com
34 Richmond Road
Homebush,
NSW
2140
Australia
Phone:
61 2 8415 7300
Officers
| Name | Title |
|---|---|
| Dr. David Ali | CEO, MD & Executive Director |
| Mr. Pablo Neyertz | Director of Finance |
| Associate Prof. Hassan Bakos | Director of Operations |
| Prof. R. John Aitken Ph.D., ScD FRSE | Scientific Director |
| Mr. Andrew Metcalfe CPA | Company Secretary |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.058 |
| Price-to-Sales TTM: | 4.9482 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |